1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Anaplastic Lymphoma Kinase (ALK) Inhibitors -Pipeline Insights, 2016


DelveInsight’s, “Anaplastic Lymphoma Kinase (ALK) Inhibitors-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Anaplastic Lymphoma Kinase (ALK) Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Anaplastic Lymphoma Kinase (ALK) Inhibitors. DelveInsight’s Report also assesses the Anaplastic Lymphoma Kinase (ALK) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitive pipeline landscape of Anaplastic Lymphoma Kinase (ALK) Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Anaplastic Lymphoma Kinase (ALK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Anaplastic Lymphoma Kinase (ALK) Inhibitors and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Anaplastic Lymphoma Kinase (ALK) Inhibitors -Pipeline Insights, 2016

- Anaplastic Lymphoma Kinase (ALK) Inhibitors Overview
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Disease Associated
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Pipeline Therapeutics
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Therapeutics under Development by Companies
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Filed and Phase III Products
- Comparative Analysis
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Phase II Products
- Comparative Analysis
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Phase I and IND Filed Products
- Comparative Analysis
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Anaplastic Lymphoma Kinase (ALK) Inhibitors - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Anaplastic Lymphoma Kinase (ALK) Inhibitors - Discontinued Products
- Anaplastic Lymphoma Kinase (ALK) Inhibitors - Dormant Products
- Companies Involved in Therapeutics Development for Anaplastic Lymphoma Kinase (ALK) Inhibitors
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Anaplastic Lymphoma Kinase (ALK) Inhibitors by Therapy Area, 2016
- Number of Products under Development for Anaplastic Lymphoma Kinase (ALK) Inhibitors, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Monotherapy Products
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Combination Products
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Route of Administration
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Stage and Route of Administration
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Molecule Type
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Stage and Molecule Type
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Therapeutics - Discontinued Products
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Anaplastic Lymphoma Kinase (ALK) Inhibitors by Therapy Area, 2016
- Number of Products under Development for Anaplastic Lymphoma Kinase (ALK) Inhibitors, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Monotherapy Products
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Combination Products
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Route of Administration
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Stage and Route of Administration
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Molecule Type
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hodgkin’s Lymphoma in 17 Major Markets Hodgkin’s Lymphoma (HL) is a cancer (also known as Hodgkin Disease, Hodgkin Lymphoma o ...

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market  Forecast-2023

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Small lymphocytic lymphoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Cancer Statistics in the US - Forecast

  • November 2016
    8 pages
  • Cancer  

  • United States  

View report >

Cancer Statistics in Russia

  • November 2016
    8 pages
  • Leukemia  

    Cancer  

    Radiography  

  • Russian Federat...  

View report >

Related Market Segments :

Lymphoma

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.